Harold D Meyers

US Patent:

20160256467, Sep 8, 2016

Filed:

May 12, 2016

Appl. No.:

15/152703

Inventors:

- Malvern PA, US
Nabil Elshourbagy - Chester PA, US
Harold Meyers - Weston PA, US
Shaker A. Mousa - Wynantskill NY, US

International Classification:

A61K 31/5377
A61K 31/42
A61K 31/4196
A61K 31/426
A61K 31/4178
A61K 31/4439
A61K 31/4155
A61K 31/415
A61K 31/4545
A61K 31/4015
A61K 31/433
A61K 31/404

Abstract:

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.

US Patent:

20160257672, Sep 8, 2016

Filed:

Oct 6, 2014

Appl. No.:

15/028164

Inventors:

- Philadelphia PA, US
- Malvern PA, US
Rogelio Martinez - Trenton NJ, US
Victor P. Ghidu - Philadelphia PA, US
Harold Meyers - Weston MA, US
Shaker A. Mousa - Wynantskill NY, US
Nabil Elshourbagy - West Chester PA, US

International Classification:

C07D 405/12
C07D 487/08
C07D 471/08

Abstract:

The present invention relates to pharmaceutical compositions comprising furan-2-sulfonamide derivatives. The present invention further relates to methods of treatment of diseases or conditions associated with endothelial lipase activity, including coronary artery disease and low HDL-C.

US Patent:

20150374710, Dec 31, 2015

Filed:

Mar 11, 2014

Appl. No.:

14/767133

Inventors:

- Malvern PA, US
Nabil Elshourbagy - Chester PA, US
Harold Meyers - Weston PA, US
Shaker A. Mousa - Wynantskill NY, US

International Classification:

A61K 31/5377
A61K 31/42
A61K 31/4196
A61K 31/426
A61K 31/4178
A61K 31/4439
A61K 31/4155
A61K 31/415
A61K 31/4545
A61K 31/433
A61K 31/404

Abstract:

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.